239 related articles for article (PubMed ID: 26577335)
1. IgE-mediated asthma: New revelations and future insights.
Djukanovic R; Hanania N; Busse W; Price D
Respir Med; 2016 Mar; 112():128-9. PubMed ID: 26577335
[TBL] [Abstract][Full Text] [Related]
2. The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.
Bartuzi Z; Bodzenta-Łukaszyk A; Kuna P; Kupryś-Lipińska I; Niżankowska-Mogilnicka E; Samoliński B
Pneumonol Alergol Pol; 2015; 83(4):335-8. PubMed ID: 26166795
[No Abstract] [Full Text] [Related]
3. The discovery and development of omalizumab for the treatment of asthma.
Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
[TBL] [Abstract][Full Text] [Related]
4. Anti-immunoglobulin E therapy with omalizumab for asthma.
Hendeles L; Sorkness CA
Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
[TBL] [Abstract][Full Text] [Related]
5. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies.
Palomares Ó; Sánchez-Ramón S; Dávila I; Prieto L; Pérez de Llano L; Lleonart M; Domingo C; Nieto A
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635659
[TBL] [Abstract][Full Text] [Related]
6. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma].
Michils A; Sternon J
J Pharm Belg; 2006; 61(3):83-7. PubMed ID: 17058881
[TBL] [Abstract][Full Text] [Related]
7. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
Nowak D
Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
[TBL] [Abstract][Full Text] [Related]
8. Timing is everything: Targeting IgE to reduce asthma exacerbation risk.
O'Byrne PM; Tworek D
J Allergy Clin Immunol; 2015 Dec; 136(6):1486-1487. PubMed ID: 26654197
[No Abstract] [Full Text] [Related]
9. Omalizumab in asthma: an update on recent developments.
Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
[TBL] [Abstract][Full Text] [Related]
11. The use of anti-IgE therapy beyond allergic asthma.
Stokes JR; Casale TB
J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab in the Therapy of Pediatric Asthma.
Poddighe D; Brambilla I; Licari A; Marseglia GL
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):103-109. PubMed ID: 29714140
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilic Esophagitis Onset Despite Six Years' Treatment With Omalizumab in an Asthmatic Patient: No Protective Effect for Anti-IgE Therapy?
Franceschini L; Macchiarelli R; Biviano I; Farsi A
Am J Gastroenterol; 2021 Jul; 116(7):1560. PubMed ID: 33852452
[No Abstract] [Full Text] [Related]
14. The relationship between allergen immunotherapy and omalizumab for treating asthma.
Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab therapy for children and adolescents with severe allergic asthma.
Romano C
Expert Rev Clin Immunol; 2015; 11(12):1309-19. PubMed ID: 26312385
[TBL] [Abstract][Full Text] [Related]
16. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.
Samitas K; Delimpoura V; Zervas E; Gaga M
Eur Respir Rev; 2015 Dec; 24(138):594-601. PubMed ID: 26621973
[TBL] [Abstract][Full Text] [Related]
17. Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult Asthma.
Mizuma H; Tanaka A; Uchida Y; Fujiwara A; Manabe R; Furukawa H; Kuwahara N; Fukuda Y; Kimura T; Jinno M; Ohta S; Yamamoto M; Matsukura S; Adachi M; Sagara H
Int Arch Allergy Immunol; 2015; 168(3):165-72. PubMed ID: 26790100
[TBL] [Abstract][Full Text] [Related]
18. A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens.
Johansson SGO; Lilja G; Hallberg J; Nopp A
Immun Inflamm Dis; 2018 Sep; 6(3):382-391. PubMed ID: 29737044
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI.
Maggi L; Rossettini B; Montaini G; Matucci A; Vultaggio A; Mazzoni A; Palterer B; Parronchi P; Maggi E; Liotta F; Annunziato F; Cosmi L
Eur J Immunol; 2018 Dec; 48(12):2005-2014. PubMed ID: 30252930
[TBL] [Abstract][Full Text] [Related]
20. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
D'Amato G
Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
